17 completed, 3 terminated, 2 withdrawn. 13 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Terminated 2 |
| Phase 2 | 12 | Completed 8, Terminated 2, Withdrawn 2 |
Follow dalotuzumab: new trials by email Literature Review of dalotuzumab trials Research Report on dalotuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) Dalotuzumab, Irinotecan, Cetuximab - Rectal Neoplasms | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 11 | 2012-07-06 | 2020-05-04 |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) Ridaforolimus, Dalotuzumab, Exemestane - Breast Neoplasms | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2012-07-04 | 2019-03-25 |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) dalotuzumab, ridaforolimus - Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 21 | 2012-02-01 | 2016-06-17 |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) dalotuzumab, MK-0752, ridaforolimus - Neoplasms Malignant | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 47 | 2010-11-22 | 2018-08-16 |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) ridaforolimus + dalotuzumab, exemestane, ridaforolimus - Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 115 | 2010-09-17 | 2017-05-31 |
| The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) Ridaforolimus + Dalotuzumab, Ridaforolimus, Dalotuzumab - Breast Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 63 | 2010-09-01 | 2015-01-21 |
| FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer MK-0646, Placebo - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2010-09-01 | 2011-12-05 | |
| MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer anti-IGF-1R recombinant monoclonal antibody MK-0646, cisplatin, etoposide - Lung Cancer | Phase 1 / Phase 2 | Completed | NCIC Clinical Trials Group | 12 | 2009-12-16 | 2023-08-04 |
| Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Fulvestrant, MK-0646, Dasatinib - Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2009-11-01 | 2015-02-02 |
| Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) Dalotuzumab 10 mg/kg, Cetuximab, Irinotecan - Colorectal Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2009-06-17 | 2018-08-15 |
| MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646 - Non Small Cell Lung Cancer | Phase 2 | Completed | University of Kansas | 27 | 2009-06-01 | 2014-11-07 |
| Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) Comparator: erlotinib + dalotuzumab, Comparator: erlotinib monotherapy - Carcinoma, Non-small Cell Lung | Phase 1 | Completed | Merck Sharp & Dohme LLC | 49 | 2009-02-01 | 2016-04-04 |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer MK-0646, Gemcitabine, Erlotinib - Pancreatic Cancer, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 81 | 2008-11-13 | 2020-09-03 |
| A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) dalotuzumab (MK0646) - Breast Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 48 | 2008-09-30 | 2018-08-15 |
| Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) Dalotuzumab - Neoplasm | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2008-08-04 | 2018-08-08 |
| A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) Comparator: ridaforolimus + dalotuzumab - Neoplasms | Phase 1 | Completed | Merck Sharp & Dohme LLC | 87 | 2008-07-01 | 2015-02-10 |
| A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) Dalotuzumab, Erlotinib - Carcinoma, Non-small-cell Lung | Phase 2 | Completed | Merck Sharp & Dohme LLC | 95 | 2008-03-19 | 2018-08-08 |
| Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) MK-0646 - Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2008-01-01 | 2015-11-20 |
| Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) dalotuzumab, irinotecan hydrochloride, cetuximab - Metastatic Colorectal Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 558 | 2007-12-24 | 2018-08-08 |
| A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) dalotuzumab - Advanced Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 50 | 2006-08-07 | 2018-10-09 |
Showing 20 of 22. Sign in to see all of them.
Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Lung Neoplasms (3) · Neoplasms (3) · Adenocarcinoma (1) · Fallopian Tube Neoplasms (1) · Insulin-Like Growth Factor I, Resistance To (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Pleural Effusion (1) · Rectal Neoplasms (1)
Merck Sharp & Dohme LLC (15) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Memorial Sloan Kettering Cancer Center (1) · NCIC Clinical Trials Group (1) · University of Kansas (1)
United States (4) · Canada (1)
Ana Gonzalez-Angulo, MD, MS (1) · Chao H Huang, MD, FACP (1) · Grace K. Dy, MD (1) · Leonard Saltz, MD (1) · Milind Javle, MD (1) · Peter Ellis, MD (1)
PMID 21810918, PMID 23921573, PMID 24518092, PMID 25290091, PMID 25320355, PMID 25414803, PMID 26793618, PMID 27185573, PMID 28324268, PMID 28681171, PMID 29843755
2008 (1)